Gold prices steady ahead of Fed decision, Trump’s tariff deadline
In a challenging market environment, Rani Therapeutics Holdings, Inc. (RANI) stock has touched a 52-week low, trading at $1.24, marking a sharp decline from its 52-week high of $8.75. With a market capitalization of just $72.4 million, the company’s InvestingPro analysis indicates the stock is currently trading below its Fair Value. This price level reflects a significant downturn for the company, which specializes in the development of oral biologics. Over the past year, Rani Therapeutics has seen its stock value decrease by a staggering 59.87%, indicating a tough period for investors and the company alike. The biotech firm, known for its innovative approach to drug delivery, has faced industry-wide pressures that have impacted its stock performance, leading to this new low point in its market valuation. Analysts maintain optimism with price targets ranging from $8 to $17, though InvestingPro data reveals the company is quickly burning through cash with an EBITDA of -$50.8 million in the last twelve months. For deeper insights and access to 10 additional ProTips about RANI, consider exploring the comprehensive Pro Research Report available on InvestingPro.
In other recent news, Rani Therapeutics Holdings Inc. reported its financial results for the fourth quarter of 2024, revealing a net loss of $56.6 million, an improvement from $67.9 million in the previous year. The company’s earnings per share were slightly below expectations, with an actual EPS of -0.27 compared to the forecast of -0.26. Despite this, Rani Therapeutics introduced its first contract revenue of $1 million in 2024. The company ended the year with $27.6 million in cash and equivalents, which is expected to fund operations into the third quarter of 2025.
BTIG maintained a Buy rating on Rani Therapeutics, setting a price target of $14.00. The research firm highlighted the potential of Rani’s RT-114, a RaniPill containing an Fc fusion GLP1/2 agonist, to make a significant impact in the oral obesity treatment market. This is due to its improved tolerability and lower manufacturing costs compared to other treatments. The company plans to initiate a Phase 1 trial for RT-114 in mid-2025, targeting obese patients.
Rani Therapeutics is also exploring opportunities in obesity, immunology, and rare diseases, with potential international market expansion for its oral semaglutide product. The company’s strategic focus on cost containment has led to a decrease in both research and development expenses and general and administrative expenses. These developments reflect ongoing efforts to enhance the company’s financial health and operational efficiency.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.